Intellectual Property
We have an exclusive license to a patent portfolio created by the original developers of our alphavirus technology -- the University of North Carolina at Chapel Hill and the US Army Medical Research Institute of Infectious Diseases (USAMRIID). A wide range of patents and their patent families have been added to this base. Concomitant with ongoing improvements achieved as the technology has been implemented, our IP portfolio has been, and continues to be, expanded. Our alphavaccine technology has been the subject of 32 issued US patents, supplemented by a host of foreign counterparts, with many of the patent families pending application or approvals.
US Patents Issued: